Solubilized ketanserin binding sites from pig platelet membranes. 1985

W Wesemann, and D Hoffmann

Plasma membranes of pig platelets were isolated and subjected to solubilization with digitonin. Binding of [3H]ketanserin to the solubilized membrane fraction, optimal at pH 7.5, was time and protein dependent and was greatly reduced by increasing ionic strength of the incubation buffer. Saturation analysis and inhibition of binding with various 5-HT2 antagonists showed the presence of two binding sites with high and low affinity, respectively. High affinity binding to solubilized membrane proteins correlated well with that found in native membranes with regard to the dissociation constant KD (1.6 and 1.2 nM, respectively) and the displacement by 5-HT2 antagonists. Binding to this site was not inhibited by the dopamine antagonist haloperidol which, however, displaced [3H]ketanserin bound to the low affinity site. At present the nature of the low affinity binding site (KD = 71 nM) is not well understood. Centrifugation on sucrose gradients revealed only one peak of [3H]ketanserin binding corresponding to the molecular weight of catalase (232,000 Da), thus probably reflecting a close association of the two binding sites.

UI MeSH Term Description Entries
D007650 Ketanserin A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione,R-41,468,R-41468,R 41,468,R 41468,R41,468,R41468
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010880 Piperidines A family of hexahydropyridines.
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012702 Serotonin Antagonists Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. 5-HT Antagonist,5-HT Antagonists,5-Hydroxytryptamine Antagonist,5-Hydroxytryptamine Antagonists,Antiserotonergic Agent,Antiserotonergic Agents,Serotonin Antagonist,Serotonin Blockader,Serotonin Blockaders,Serotonin Receptor Antagonist,Serotonin Receptor Blocker,Antagonists, 5-HT,Antagonists, 5-Hydroxytryptamine,Antagonists, Serotonin,Serotonin Receptor Antagonists,Serotonin Receptor Blockers,5 HT Antagonist,5 HT Antagonists,5 Hydroxytryptamine Antagonist,5 Hydroxytryptamine Antagonists,Agent, Antiserotonergic,Agents, Antiserotonergic,Antagonist, 5-HT,Antagonist, 5-Hydroxytryptamine,Antagonist, Serotonin,Antagonist, Serotonin Receptor,Antagonists, 5 HT,Antagonists, 5 Hydroxytryptamine,Antagonists, Serotonin Receptor,Blockader, Serotonin,Blockaders, Serotonin,Blocker, Serotonin Receptor,Blockers, Serotonin Receptor,Receptor Antagonist, Serotonin,Receptor Antagonists, Serotonin,Receptor Blocker, Serotonin,Receptor Blockers, Serotonin

Related Publications

W Wesemann, and D Hoffmann
November 1979, The Journal of membrane biology,
W Wesemann, and D Hoffmann
March 1988, Journal of neurochemistry,
W Wesemann, and D Hoffmann
February 1985, European journal of pharmacology,
W Wesemann, and D Hoffmann
August 1975, FEBS letters,
W Wesemann, and D Hoffmann
June 2001, Cephalalgia : an international journal of headache,
W Wesemann, and D Hoffmann
June 1974, Prostaglandins,
W Wesemann, and D Hoffmann
June 1989, Biochemical and biophysical research communications,
Copied contents to your clipboard!